The University of Southampton
University of Southampton Institutional Repository

Treatment of lipids to reduce cardiovascular risk among people with the metabolic syndrome or type 2 diabetes

Treatment of lipids to reduce cardiovascular risk among people with the metabolic syndrome or type 2 diabetes
Treatment of lipids to reduce cardiovascular risk among people with the metabolic syndrome or type 2 diabetes
The metabolic syndrome is present in approximately 20% of general populations in developed countries and in approximately 80% of people with type 2 diabetes. High triglyceride levels, low high-density cholesterol levels and central obesity are three of the five features of the metabolic syndrome and contribute to the increased risk of cardiovascular disease (CVD) among people with the metabolic syndrome. Lifestyle interventions and treatment with statins reduce risk of CVD but absolute risk of cardiovascular events among high-risk populations remains high. This article reviews the options for treating the atherogenic dyslipidaemia associated with the metabolic syndrome.
315-319
Wild, Sarah H.
b790195a-4aae-421b-81f7-2c18c96e6870
Byrne, Christopher D.
1370b997-cead-4229-83a7-53301ed2a43c
Wild, Sarah H.
b790195a-4aae-421b-81f7-2c18c96e6870
Byrne, Christopher D.
1370b997-cead-4229-83a7-53301ed2a43c

Wild, Sarah H. and Byrne, Christopher D. (2005) Treatment of lipids to reduce cardiovascular risk among people with the metabolic syndrome or type 2 diabetes. British Journal of Diabetes and Vascular Disease, 5 (6), 315-319.

Record type: Article

Abstract

The metabolic syndrome is present in approximately 20% of general populations in developed countries and in approximately 80% of people with type 2 diabetes. High triglyceride levels, low high-density cholesterol levels and central obesity are three of the five features of the metabolic syndrome and contribute to the increased risk of cardiovascular disease (CVD) among people with the metabolic syndrome. Lifestyle interventions and treatment with statins reduce risk of CVD but absolute risk of cardiovascular events among high-risk populations remains high. This article reviews the options for treating the atherogenic dyslipidaemia associated with the metabolic syndrome.

This record has no associated files available for download.

More information

Published date: 2005

Identifiers

Local EPrints ID: 26130
URI: http://eprints.soton.ac.uk/id/eprint/26130
PURE UUID: b026cda9-5b07-47b0-b31d-5162c1736b90
ORCID for Christopher D. Byrne: ORCID iD orcid.org/0000-0001-6322-7753

Catalogue record

Date deposited: 12 Apr 2006
Last modified: 23 Jul 2022 01:45

Export record

Contributors

Author: Sarah H. Wild

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×